These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33525976)

  • 1. Repurposing of FDA approved drugs and their validation against potential drug targets for
    Kesharwani A; Chaurasia DK; Katara P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6255-6271. PubMed ID: 33525976
    [No Abstract]   [Full Text] [Related]  

  • 2. Repurposing of FDA approved drugs against
    Joshi T; Sharma P; Joshi T; Mathpal S; Pande V; Chandra S
    J Biomol Struct Dyn; 2022 May; 40(8):3731-3744. PubMed ID: 33251976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradigm Shift in Drug Re-purposing From Phenalenone to Phenaleno-Furanone to Combat Multi-Drug Resistant
    Mujawar S; Gatherer D; Lahiri C
    Front Cell Infect Microbiol; 2018; 8():402. PubMed ID: 30488026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the Subtractive Genomics and Molecular Docking Analysis for the Identification of Novel Putative Drug Targets against
    Hossain T; Kamruzzaman M; Choudhury TZ; Mahmood HN; Nabi AHMN; Hosen MI
    Biomed Res Int; 2017; 2017():3783714. PubMed ID: 28904956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics driven approach for identification of novel therapeutic targets in Salmonella enterica.
    Gawade P; Ghosh P
    Gene; 2018 Aug; 668():211-220. PubMed ID: 29778427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing of approved drug molecules for viral infectious diseases: a molecular modelling approach.
    Kumar N; Sarma H; Sastry GN
    J Biomol Struct Dyn; 2022 Oct; 40(17):8056-8072. PubMed ID: 33810775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-based drug repurposing against Candida albicans-A computational modeling, docking, and molecular dynamic simulations study.
    Verma R; Pradhan D; Nayek A; Singh H; Jain AK; Khan LA
    J Cell Biochem; 2022 Feb; 123(2):289-305. PubMed ID: 34672012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential molecular targets and repurposed drugs for tuberculosis using network-based screening approach, molecular docking, and simulation.
    Krishnan A; Khan FI; Sukumar S; Khan MKA
    J Biomol Struct Dyn; 2023 Nov; ():1-19. PubMed ID: 37948198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation.
    Jahantigh H; Ahmadi N; Lovreglio P; Stufano A; Enayatkhani M; Shahbazi B; Ahmadi K
    J Biomol Struct Dyn; 2023 Jul; 41(11):5057-5066. PubMed ID: 35612907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep-learning based repurposing of FDA-approved drugs against
    Joshi T; Pundir H; Chandra S
    J Biomol Struct Dyn; 2022 Nov; 40(18):8420-8436. PubMed ID: 33879017
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular docking and dynamics approach to
    Halder D; Das S; Joseph A; Jeyaprakash RS
    J Biomol Struct Dyn; 2023 May; 41(8):3462-3475. PubMed ID: 35285757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of FDA approved drugs for finding potential inhibitors against Granzyme B as a potent drug-repurposing target.
    Ikram S; Ahmad J; Durdagi S
    J Mol Graph Model; 2020 Mar; 95():107462. PubMed ID: 31786094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing FDA-approved drugs as NLRP3 inhibitors against inflammatory diseases: machine learning and molecular simulation approaches.
    Agarwal V; Haldhar R; Hirad AH; Ahmed B; Han SB; Gupta A; Raj V; Lee S
    J Biomol Struct Dyn; 2024 Feb; ():1-13. PubMed ID: 38400742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the interactions between repurposed drugs sertindole and temoporfin with receptor for advanced glycation endproducts: Therapeutic implications in cancer and metabolic diseases.
    Shamsi A; Shahwan M; Anwar S; Ashames A; Khan MS; Yadav DK
    J Mol Model; 2024 May; 30(6):170. PubMed ID: 38753123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
    Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
    J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-silico identification of novel DDI2 inhibitor in glioblastoma
    Roy PK; Majumder R; Mandal M
    J Biomol Struct Dyn; 2024 Mar; 42(5):2270-2281. PubMed ID: 37139547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in
    Rani J; Silla Y; Borah K; Ramachandran S; Bajpai U
    J Biomol Struct Dyn; 2020 Jun; 38(9):2521-2532. PubMed ID: 31244382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.